`
`v.
`
`
`
`ABBVIE INC. and ABBVIE
`BIOTECHNOLOGY LTD
`
`
`
`BOEHRINGER INGELHEIM
`INTERNATIONAL GMBH,
`BOEHRINGER INGELHEIM
`PHARMACEUTICALS, INC., and
`BOEHRINGER INGELHEIM
`FREMONT, INC.
`
`
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`CIVIL NO. 17-cv-01065-MSG-RL
`
`:
`:
`:
`:
`:
`:
`:
`:
`:
` :
`:
`
`O R D E R
`
`
`
`On April 25, 2019, I held a telephone conference call on the record in this matter
`
`concerning discover disputes between the parties, collectively referred to as “AbbVie”
`
`(plaintiffs) and “Boehringer” (defendants). As directed during the conference call, it is
`
`on this 26th day of April, 2019,
`
`ORDERED
`
`As follows:
`
`1. AbbVie will file a motion to compel regarding Boehringer’s search terms related
`
`to Interrogatory No. 21. The motion will include the search terms at issue and
`
`AbbVie’s justifications for requesting broader terms.
`
`2. AbbVie will file a motion to compel relating to the alleged non-responsiveness by
`
`Boehringer to AbbVie’s Interrogatories and Requests for Admissions.
`
`3. Boehringer will provide AbbVie with all aBLA documents submitted to or
`
`received from the FDA from May 2018 until April 25, 2019. These documents
`
`shall be supplied to AbbVie by May 2, 2019. The parties should meet and confer
`
`on the issue of whether future correspondence with the FDA should be provided.
`
`
`
`Case 1:17-cv-01065-MSG-RL Document 491 Filed 04/26/19 Page 2 of 3 PageID #: 15276
`
`4. AbbVie will file a motion to compel concerning the allegedly improper redactions
`
`in Boehringer’s document productions. AbbVie will also submit no more than
`
`fifteen (15) documents to support their argument.
`
`5. Boehringer will file a motion regarding AbbVie’s notices of deposition of
`
`Boehringer’s apex witnesses and in-house litigation counsel.
`
`6. Boehringer will file a motion concerning AbbVie’s allegedly improper clawback of
`
`documents.
`
`7. AbbVie will advise Boehringer of the status of the search of the storage facility
`
`referenced during the telephone conference held on April 25, 2019. This status
`
`update will include an estimate of the length of time to search the facility, the
`
`amount of documents that are located at the facility, and the categories of
`
`documents that AbbVie has learned are located at the facility.
`
`8. AbbVie will also provide more complete answers to Boehringer’s Interrogatory
`
`No. 42 and Interrogatory No. 43.
`
`9. Boehringer is permitted to re-depose Yu-Hsiang Chang with the document
`
`containing the now-correct metadata. AbbVie will pay for the costs and attorneys’
`
`fees relating to the re-deposition.
`
`10. Boehringer may re-raise the issues regarding prior art presentations if the
`
`directives in paragraphs seven (7), eight (8), and nine (9) prove inadequate to
`
`cure prejudice. However, I will defer any motions on this issue until the parties
`
`have completed the directives stated in paragraphs seven (7), eight (8), and nine
`
`(9) of this Order and have met and conferred to resolve any remaining issues. In
`
`the event that issues remain, the parties may schedule a telephone call with me.
`
`
`
`Case 1:17-cv-01065-MSG-RL Document 491 Filed 04/26/19 Page 3 of 3 PageID #: 15277
`
`11. Boehringer will file a motion to compel the production of documents relating to
`
`AbbVie’s prior art sales.
`
`12. AbbVie will submit a letter to my chambers detailing the background and history
`
`of the issue involving the production of AbbVie’s internal prosecution files,
`
`specifically what was (and was not) agreed to in the April 2018 agreement and
`
`November 2018 letter. This letter must be submitted no later than May 2, 2019.
`
`Boehringer may submit a responsive letter due no later than May 9, 2019. After
`
`considering these letters, I will decide whether motions on the issue of the
`
`production of AbbVie’s internal prosecution files are necessary.
`
`13. The parties will meet and confer about the language relating to AbbVie’s dates of
`
`conception and reduction to practice for the asserted claims. If the parties cannot
`
`agree, Boehringer will file an appropriate motion.
`
`14. For the motions referenced in this Order, each party will submit one brief
`
`containing the party’s respective motions. These briefs are due no later than
`
`May 16, 2019. Responsive memoranda are due May 30, 2019. Reply briefs
`
`will not be permitted except on request and for good cause.
`
`BY THE COURT:
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`_s/Richard A. Lloret_
`RICHARD A. LLORET
`U.S. MAGISTRATE JUDGE
`
`
`
`
`
`